Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment

By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left...

Related Keywords

Australia ,Australian , ,Drug Administration ,Dean Seal ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Biopharmaceuticals ,Biological Therapy ,Healthcare Provision ,Regulation Government Policy ,Corporate Industrial News ,Political General News ,Demographic Health ,Health ,Infant Child Teenage Health ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Mesoblast ,Msb Au ,Au Msb ,Regulation ,Government Policy ,Corporate ,Industrial News ,Political ,General News ,Infant ,Child ,Teenage Health ,Healthcare ,Life Sciences ,